Back to results

A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)

Primary Purpose

Amyotrophic Lateral Sclerosis

Status

Completed

Phase

Phase 1

Locations

United States

Study Type

Interventional

Intervention

ibudilast

About this trial

This is an interventional treatment trial for Amyotrophic Lateral Sclerosis focused on measuring ALS

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subjects must be diagnosed as having possible, probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria.
Age 18 or above, able to provide informed consent, and safely comply with study procedures.
Vital capacity (VC) of at least 50% predicted value for gender, height and age at screening visit, or in the opinion of the study physician, able to safely tolerate study procedures. (Not applicable to flexible arm)
Subject must be able to swallow oral medication at the Baseline Visit and expected to be able to swallow the capsules throughout the course of the study.
Subject must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study). (Not applicable to flexible arm)
Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control) for the duration of the study and 3 months after study completion.
Males should practice contraception for the duration of the study and 3 months after completion.
Ability to safely lie flat for 90 min for PET procedures in the opinion of the study physician. (Not applicable to flexible arm)
High or mixed affinity to bind TSPO protein (Ala/Ala or Ala/Thr) (see section 7.2.1). (Not applicable to flexible arm)
Upper motor Neuron Burden (UMNB) Score ≥25 (out of 45) at screening visit. (Not applicable to flexible arm)

Exclusion Criteria:

Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal.
Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal.
The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to PI judgment.
Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the study.
History of HIV, clinically significant chronic hepatitis, or other active infection.
Active inflammatory condition of autoimmune disorder (Not applicable to flexible arm)
Females must not be lactating or pregnant.
Active participation in another ALS clinical trial or exposure to an off label ALS experimental treatment within 30 days of the Baseline Visit (Not applicable to flexible arm)
Exposure to immunomodulatory medications within 30 days of the Baseline Visit. (Not applicable to flexible arm)
Any contraindication to undergo MRI studies such as
- History of a cardiac pacemaker or pacemaker wires
- Metallic particles in the body
- Vascular clips in the head
- Prosthetic heart valves
- Claustrophobia (Not applicable to flexible arm)
Radiation exposure that exceeds the site's current guidelines (Not applicable to flexible arm)
EKG finding of QTc prolongation > 450 ms for males and > 470 ms for females at screening or baseline.
Not on any prohibitive medication or known QT prolonging medication:

Sites / Locations

Massachusetts General Hospital
South Shore Neurologic Associates, P.C.

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

MN-166 (ibudilast)

Arm Description

MN-166 (ibudilast) 10 mg capsules administered orally. Fifty (50) mg b.i.d. (5 capsules) in the morning and 50 mg b.i.d. (5 capsules) evening will be administered for a total daily dose of 100 mg/d. Study drug dosing may vary based on individual tolerability.

Outcomes

Primary Outcome Measures

To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks

This is measured as the ratio of standardized uptake value (SUVR).

To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers

Blood biomarkers for neuroinflammation include tumor necrosis factor(TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-1, IL-6, and IL-10. All blood biomarkers are measured in picrograms/milliliter (pg/mL).

Secondary Outcome Measures

To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events.

To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R)

ALSFRS-R is a clinical assessment for function. It measures speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. The scale ranges from 0 (no ability) to 4 (normal ability). The Total Score of these sub-assessments is the ALSFRS-R score.

To evaluate the effect of ibudilast on slow vital capacity (SVC)

SVC is measured as SVC predicted liters.

To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD)

HHD assesses strength and is measured in kilograms (kg).

Full Information

NCT ID

NCT02714036

First Posted

March 9, 2016

Last Updated

July 20, 2020

Sponsor

MediciNova

Collaborators

Massachusetts General Hospital, South Shore Neurologic Associates

1. Study Identification

Unique Protocol Identification Number

NCT02714036

Brief Title

A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)

Official Title

A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)

Study Type

Interventional

2. Study Status

Record Verification Date

July 2020

Overall Recruitment Status

Completed

Study Start Date

May 6, 2016 (Actual)

Primary Completion Date

December 31, 2019 (Actual)

Study Completion Date

June 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

MediciNova

Collaborators

Massachusetts General Hospital, South Shore Neurologic Associates

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

Detailed Description

This is a multi-center, open-label study of MN-166 (ibudilast) in subjects with ALS. To be eligible subjects must meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS. Safety, tolerability, blood, neuro-imaging biomarkers, and clinical outcomes will be collected on all subjects. Subjects will receive study drug for 36 weeks. The study will consist of a Screening Phase (up to 6 weeks), an Open-Label Treatment Phase (36 weeks) and a Off-Treatment Follow-up Phase (4 Weeks). During the Screening Phase, eligible ALS subjects will sign an informed consent form and the following screening assessments will be performed: review of inclusion/exclusion criteria: El Escorial ALS Diagnostic criteria, medical history and demographics, ALS diagnosis history, physical and neurological examination, U. Penn upper motor Neuron Burden (UMNB), pulmonary function tests, vital signs including height and weight, blood for safety labs including TSPO affinity test, ECG and review and documentation of concomitant medications and therapies. Screening Phase (up to 6 weeks) The Treatment Phase will consist of a Baseline visit and 3 subsequent clinic visits at Weeks 4, 12, 24, and 36. Telephone follow-ups will occur at Weeks 1, 2, 8, 16, 20, 28, and 32. Open-Label Treatment Phase (36 weeks) At the Baseline visit, subjects will return to the clinic and the following assessments will be performed/administered: review of inclusion and exclusion criteria for continued eligibility, vital signs, blood for safety labs and biomarkers, ECG, ALSFRS-R questionnaire, slow vital capacity (SVC), baseline strength as measured by hand held dynamometry (HHD), and Columbia Suicide Severity Rating Scale (C-SSRS). At this visit, study drug will be dispensed, and adverse events, concomitant medications and therapies will be assessed and documented. At subsequent visits during the Treatment Phase, similar assessments will be performed. In addition, a [11C]PBR28-PET scan will be performed once between the Screening and Baseline visit, and once between the Week 20 and Week 28 phone calls. The ALSFRS-R, SVC and U Penn Upper Motor Neuron Burden will be repeated on the same day as the PET scans. The follow-up visit will consist of a telephone call to document adverse events and concomitant therapies

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Amyotrophic Lateral Sclerosis

Keywords

ALS

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1, Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

35 (Actual)

8. Arms, Groups, and Interventions

Arm Title

MN-166 (ibudilast)

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

ibudilast

Other Intervention Name(s)

MN-166, AV411

Intervention Description

Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration16. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.

Primary Outcome Measure Information:

Title

To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks

Description

This is measured as the ratio of standardized uptake value (SUVR).

Time Frame

24 weeks

Title

To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers

Description

Time Frame

36 weeks

Secondary Outcome Measure Information:

Title

To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events.

Time Frame

36 weeks

Title

To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R)

Description

Time Frame

36 weeks

Title

To evaluate the effect of ibudilast on slow vital capacity (SVC)

Description

SVC is measured as SVC predicted liters.

Time Frame

36 weeks

Title

To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD)

Description

HHD assesses strength and is measured in kilograms (kg).

Time Frame

36 weeks

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Subjects must be diagnosed as having possible, probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria. Age 18 or above, able to provide informed consent, and safely comply with study procedures. Vital capacity (VC) of at least 50% predicted value for gender, height and age at screening visit, or in the opinion of the study physician, able to safely tolerate study procedures. (Not applicable to flexible arm) Subject must be able to swallow oral medication at the Baseline Visit and expected to be able to swallow the capsules throughout the course of the study. Subject must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study). (Not applicable to flexible arm) Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control) for the duration of the study and 3 months after study completion. Males should practice contraception for the duration of the study and 3 months after completion. Ability to safely lie flat for 90 min for PET procedures in the opinion of the study physician. (Not applicable to flexible arm) High or mixed affinity to bind TSPO protein (Ala/Ala or Ala/Thr) (see section 7.2.1). (Not applicable to flexible arm) Upper motor Neuron Burden (UMNB) Score ≥25 (out of 45) at screening visit. (Not applicable to flexible arm) Exclusion Criteria: Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal. Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to PI judgment. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the study. History of HIV, clinically significant chronic hepatitis, or other active infection. Active inflammatory condition of autoimmune disorder (Not applicable to flexible arm) Females must not be lactating or pregnant. Active participation in another ALS clinical trial or exposure to an off label ALS experimental treatment within 30 days of the Baseline Visit (Not applicable to flexible arm) Exposure to immunomodulatory medications within 30 days of the Baseline Visit. (Not applicable to flexible arm) Any contraindication to undergo MRI studies such as History of a cardiac pacemaker or pacemaker wires Metallic particles in the body Vascular clips in the head Prosthetic heart valves Claustrophobia (Not applicable to flexible arm) Radiation exposure that exceeds the site's current guidelines (Not applicable to flexible arm) EKG finding of QTc prolongation > 450 ms for males and > 470 ms for females at screening or baseline. Not on any prohibitive medication or known QT prolonging medication:

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Suma Babu, MBBS, MPH

Organizational Affiliation

Massachusetts General Hospital

Official's Role

Principal Investigator

Facility Information:

Facility Name

Massachusetts General Hospital

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02114

Country

United States

Facility Name

South Shore Neurologic Associates, P.C.

City

Patchogue

State/Province

New York

ZIP/Postal Code

11772

Country

United States

12. IPD Sharing Statement

Plan to Share IPD

Citations:

PubMed Identifier

24126629

Citation

Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013 Nov;9(11):617-28. doi: 10.1038/nrneurol.2013.203. Epub 2013 Oct 15.

Results Reference

background

PubMed Identifier

19922118

Citation

Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG; Eurals Consortium. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23. doi: 10.3109/17482960802566824.

Results Reference

background

PubMed Identifier

23860588

Citation

Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118-30. doi: 10.1159/000351153. Epub 2013 Jul 11.

Results Reference

background

PubMed Identifier

23415570

Citation

Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, Nicholson G, Ravits J, Shaw PJ, Swash M, Talbot K, Traynor BJ, Van den Berg LH, Veldink JH, Vucic S, Kiernan MC. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013 Mar;12(3):310-22. doi: 10.1016/S1474-4422(13)70036-X.

Results Reference

background

PubMed Identifier

22419278

Citation

Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD001447. doi: 10.1002/14651858.CD001447.pub3.

Results Reference

background

PubMed Identifier

16337133

Citation

Henkel JS, Beers DR, Siklos L, Appel SH. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci. 2006 Mar;31(3):427-37. doi: 10.1016/j.mcn.2005.10.016. Epub 2005 Dec 5.

Results Reference

background

PubMed Identifier

16741123

Citation

Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006 Jun 2;312(5778):1389-92. doi: 10.1126/science.1123511.

Results Reference

background

PubMed Identifier

22863620

Citation

Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, Lawson R, Berry J, Krichevsky AM, Cudkowicz ME, Weiner HL. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012 Sep;122(9):3063-87. doi: 10.1172/JCI62636. Epub 2012 Aug 6.

Results Reference

background

PubMed Identifier

23740943

Citation

Koval ED, Shaner C, Zhang P, du Maine X, Fischer K, Tay J, Chau BN, Wu GF, Miller TM. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet. 2013 Oct 15;22(20):4127-35. doi: 10.1093/hmg/ddt261. Epub 2013 Jun 4.

Results Reference

background

PubMed Identifier

23686809

Citation

Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Y, Kwong L, Lee EB, Elman L, McCluskey L, Fang L, Feldengut S, Ludolph AC, Lee VM, Braak H, Trojanowski JQ. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013 Jul;74(1):20-38. doi: 10.1002/ana.23937. Epub 2013 Jun 19.

Results Reference

background

PubMed Identifier

14755726

Citation

Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004 Feb;55(2):221-35. doi: 10.1002/ana.10805.

Results Reference

background

PubMed Identifier

19236470

Citation

Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol. 2009 Jun;16(6):771-4. doi: 10.1111/j.1468-1331.2009.02560.x. Epub 2009 Feb 19.

Results Reference

background

PubMed Identifier

16380619

Citation

Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destee A, Tonnel AB, Lassalle P, Just N. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology. 2005 Dec 27;65(12):1958-60. doi: 10.1212/01.wnl.0000188907.97339.76.

Results Reference

background

PubMed Identifier

25685708

Citation

Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015 Jan 19;7:409-14. doi: 10.1016/j.nicl.2015.01.009. eCollection 2015.

Results Reference

background

PubMed Identifier

19925385

Citation

Sanftner LM, Gibbons JA, Gross MI, Suzuki BM, Gaeta FC, Johnson KW. Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica. 2009 Dec;39(12):964-77. doi: 10.3109/00498250903254340.

Results Reference

background

PubMed Identifier

20534506

Citation

Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K, Lolis EJ. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11313-8. doi: 10.1073/pnas.1002716107. Epub 2010 Jun 8.

Results Reference

background

PubMed Identifier

23797673

Citation

Cox GM, Kithcart AP, Pitt D, Guan Z, Alexander J, Williams JL, Shawler T, Dagia NM, Popovich PG, Satoskar AR, Whitacre CC. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. J Immunol. 2013 Aug 1;191(3):1043-54. doi: 10.4049/jimmunol.1200485. Epub 2013 Jun 24.

Results Reference

background

PubMed Identifier

14604772

Citation

Wakita H, Tomimoto H, Akiguchi I, Lin JX, Ihara M, Ohtani R, Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res. 2003 Nov 28;992(1):53-9. doi: 10.1016/j.brainres.2003.08.028.

Results Reference

background

PubMed Identifier

10434004

Citation

Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999 Aug 7;837(1-2):203-12. doi: 10.1016/s0006-8993(99)01666-2.

Results Reference

background

PubMed Identifier

14975696

Citation

Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004 Mar;46(3):404-11. doi: 10.1016/j.neuropharm.2003.09.009.

Results Reference

background

PubMed Identifier

21494611

Citation

Kiebala M, Maggirwar SB. Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells. PLoS One. 2011 Apr 8;6(4):e18633. doi: 10.1371/journal.pone.0018633.

Results Reference

background

PubMed Identifier

15813970

Citation

Kagitani-Shimono K, Mohri I, Fujitani Y, Suzuki K, Ozono K, Urade Y, Taniike M. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation. 2005 Apr 6;2(1):10. doi: 10.1186/1742-2094-2-10.

Results Reference

background

PubMed Identifier

10229113

Citation

Fujimoto T, Sakoda S, Fujimura H, Yanagihara T. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol. 1999 Mar 1;95(1-2):35-42. doi: 10.1016/s0165-5728(98)00251-3.

Results Reference

background

PubMed Identifier

20200338

Citation

Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010 Mar 30;74(13):1033-40. doi: 10.1212/WNL.0b013e3181d7d651. Epub 2010 Mar 3.

Results Reference

background

PubMed Identifier

16674936

Citation

Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol. 2006 May 24;538(1-3):39-42. doi: 10.1016/j.ejphar.2006.02.053. Epub 2006 Mar 13.

Results Reference

background

PubMed Identifier

8800577

Citation

Tominaga Y, Nakamura Y, Tsuji K, Shibata T, Kataoka K. Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons. Clin Exp Pharmacol Physiol. 1996 Jun-Jul;23(6-7):519-23. doi: 10.1111/j.1440-1681.1996.tb02772.x.

Results Reference

background

PubMed Identifier

11454657

Citation

Takuma K, Lee E, Enomoto R, Mori K, Baba A, Matsuda T. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br J Pharmacol. 2001 Jul;133(6):841-8. doi: 10.1038/sj.bjp.0704146.

Results Reference

background

PubMed Identifier

9603206

Citation

Yoshioka A, Shimizu Y, Hirose G, Kitasato H, Pleasure D. Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity. J Neurochem. 1998 Jun;70(6):2416-23. doi: 10.1046/j.1471-4159.1998.70062416.x.

Results Reference

background

PubMed Identifier

20200341

Citation

Fox RJ. Primary neuroprotection: the Holy Grail of multiple sclerosis therapy. Neurology. 2010 Mar 30;74(13):1018-9. doi: 10.1212/WNL.0b013e3181d6b165. Epub 2010 Mar 3. No abstract available.

Results Reference

background

PubMed Identifier

22008728

Citation

Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5. doi: 10.1038/jcbfm.2011.147. Epub 2011 Oct 19.

Results Reference

background

PubMed Identifier

22968319

Citation

Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL, Zoghbi SS, Hyde T, Kleinman JE, Pike VW, McMahon FJ, Innis RB; Biomarkers Consortium PET Radioligand Project Team. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013 Jan;33(1):53-8. doi: 10.1038/jcbfm.2012.131. Epub 2012 Sep 12.

Results Reference

background

PubMed Identifier

25381879

Citation

Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O, Lawson RJ, Frosch MP, Pochet N, Fatimy RE, Krichevsky AM, Gygi SP, Lassmann H, Berry J, Cudkowicz ME, Weiner HL. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015 Jan;77(1):75-99. doi: 10.1002/ana.24304. Epub 2014 Nov 27. Erratum In: Ann Neurol. 2015 Jun;77(6):1085.

Results Reference

background

PubMed Identifier

34016561

Citation

Babu S, Hightower BG, Chan J, Zurcher NR, Kivisakk P, Tseng CJ, Sanders DL, Robichaud A, Banno H, Evora A, Ashokkumar A, Pothier L, Paganoni S, Chew S, Dojillo J, Matsuda K, Gudesblatt M, Berry JD, Cudkowicz ME, Hooker JM, Atassi N. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. Neuroimage Clin. 2021;30:102672. doi: 10.1016/j.nicl.2021.102672. Epub 2021 Apr 15.

Results Reference

derived

Learn more about this trial

A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)

We'll reach out to this number within 24 hrs